Navigation Links
Mersana Therapeutics Initiates Phase 1b Extension Study of XMT-1001 in Gastric Cancer and Non-Small Cell Lung Cancer
Date:3/25/2011

CAMBRIDGE, Mass., March 25, 2011 /PRNewswire/ -- Mersana Therapeutics today announced  the initiation of a Phase 1b extension study with its lead cancer product, XMT-1001, a novel DNA topoisomerase I inhibitor based on the company's Fleximer® polymer conjugate platform, in second-line gastric cancer and second-/third-line non-small cell lung cancer.  The study will be carried out in 10 clinical centers in the US.  The Phase 1b follows the successful completion of a 74-patient Phase 1 clinical trial, which demonstrated high and prolonged plasma levels of XMT-1001 active release products and a safety profile free of the toxicities normally associated with topoisomerase 1 inhibitors, such as hemorrhagic cystitis and diarrhea.  Additionally, XMT-1001 showed promising evidence of clinical activity, including tumor shrinkage and prolonged stable disease, in a heavily pre-treated patient population.  

"Our recently completed Phase 1 study has confirmed the potential efficacy and safety advantages of the unique design of our lead Fleximer conjugate, XMT-1001," said Nick Bacopoulos, Ph.D., Chief Executive Officer of Mersana.  "We believe we are now able to fully explore the broad anti-tumor potential of XMT-1001 and are excited to initiate recruitment in our Phase 1b program."

"Our clinical experience with XMT-1001 to date suggests that it can be safely given up to doses limited by its mechanism, and thus may be useful in maximizing the therapeutic potential of its class.  The potential benefit of this agent in second-line gastric cancer and in second-/third-line non-small cell lung cancer, areas of great medical need, is well worth investigating," said Edward A. Sausville, M.D., Ph.D, Professor of Medicine and Associate Director for Clin
'/>"/>

SOURCE Mersana Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Mersana Therapeutics Reports Phase I Results for XMT-1001 in Patients with Solid Tumors at AACR-NCI-EORTC International Conference
2. Mersana Therapeutics Provides Clinical Update from Ongoing Phase 1 Study of XMT-1001 in Patients with Advanced Solid Tumors
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
6. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
7. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
8. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... Pharmacyclics, Inc. (the "Company") (NASDAQ: PCYC ... March 31, 2015, as well as general business updates. ... call will be held. Key Highlights ... 2015 increased to $206 million from $119 million for ... IMBRUVICA ® (ibrutinib) net product revenue of $247 ...
(Date:5/1/2015)... 2015  Misonix, Inc. (NASDAQ: MSON ), ... and markets innovative therapeutic ultrasonic products for spine ... laparoscopic surgery and other surgical applications, announced today ... third quarter fiscal year 2015 on Thursday, May ... call that same day, Thursday, May 7, 2015, ...
(Date:5/1/2015)... , May 1, 2015  Shares of Aerie ... of their value yesterday following the results of the ... therapy, Rhopressa.  Despite the trial failing to meet its ... positive results may come from future studies. ... company overview, current pipeline, financial review, analyst summary, valuation, ...
Breaking Medicine Technology:Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 2Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 3Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 4Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 5Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 6Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 7Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 8Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 9Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 10Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 11Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 12Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 13Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 14Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 15Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 16Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 17Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 18Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 19Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 20Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 21Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 22Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 23Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 24Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 25Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 26Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 27Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 28Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 29Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 30Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 31Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 32Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 33Misonix, Inc. To Report Third Quarter Fiscal Year 2015 Financial Results On Thursday, May 7, 2015 2All is Not Lost for Aerie Pharmaceuticals - VLM Research Issued by BrokerBank Securities, Inc. 2
... MedClean Technologies (OTC Bulletin Board: ... for the treatment and disposal of medical waste ... media, today announced it has partnered with Triumvirate ... waste disposal, engineering and remediation. This agreement will ...
... DIEGO, Oct. 20, 2011 Sequenom, Inc. (NASDAQ: SQNM ... announced it will report financial results for the third quarter of ... 3, 2011. A conference call hosted by Harry F. ... management will take place on the same day at 5:00pm ET ...
Cached Medicine Technology:MedClean Technologies Partners With Triumvirate Environmental 2MedClean Technologies Partners With Triumvirate Environmental 3Sequenom, Inc. Announces Date of Third Quarter 2011 Financial Results and Conference Call 2
(Date:5/4/2015)... Peacock Alley knows we all feel how ... was the most beautiful woman I ever saw.” , ... prints and textures to remind her just how beautiful ... Robe to get you there. The beautiful Monet-inspired print has ... waist. It is available in small/medium or large/extra large. ...
(Date:5/3/2015)... Birmingham, Lake Orion, Clarkston, Metamora, Michigan (PRWEB) May 03, 2015 ... . She has worked to enhance the well being of ... as a generalist in a hospital, followed by providing care for ... I worked with as an Adult Nurse Practitioner began wondering if ... coupled with the birth of my own children with my mentor ...
(Date:5/3/2015)... Indiana Fiber Network, LLC (IFN), the ... Services, Inc (BCS) has selected IFN as a fiber ... technology, service, and working relationship with IFN has been ... feel you get with IFN. I like dealing ... local decisions and operates as a local community business ...
(Date:5/3/2015)... May 03, 2015 It is not too late ... Aneurysm Walk in Memory of Lissa Anne Been in Arnold, ... this great family-friendly event to honor her loving memory. It has ... , Just having turned 37, Lissa suffered a brain ... on August 24, 2012. This event is designed to serve as ...
(Date:5/2/2015)... 02, 2015 “ ActOn ” was featured ... a look at the latest and coolest applications on the ... of AppWatch and technology expert, conducted the app review and ... connected with organizations to make a difference. , In this ... few things that aren’t about money, which is why those ...
Breaking Medicine News(10 mins):Health News:Feminine Classics for Mother's Day Gifts from Peacock Alley 2Health News:Women's Excellence In Midwifery Welcomes Barbara Crone 2Health News:Bank Computer Services, Inc Selects Indiana Fiber Network, LLC as Fiber Transport Provider 2Health News:Bank Computer Services, Inc Selects Indiana Fiber Network, LLC as Fiber Transport Provider 3Health News:Renowned Brain Aneurysm Foundation to Benefit from Arnold, Missouri’s 3rd Annual Brain Aneurysm Walk in Memory of Lissa Anne Been 2Health News:An Application to Help People Make a Difference Was Featured on NewsWatch Television 2
... ... provides chiropractic patients with valuable information regarding the signs and symptoms of chiropractic stroke ... ... Michael A. Abelson, who has represented people severely injured by chiropractic neck manipulations, has ...
... ... ... May 7, 2010 - Accumed Research Associates recently announced their continued growth by providing ... clinical trials facility in Garden City, NY, now offers opportunities for all phases of ...
... On ... at Costa Rica and other countries in order to answer the question: Is Costa Rica ... ... has long been the investment darling of Central America when it comes to real estate ...
... ... Summit, conducted last fall by the Southern Illinois University Edwardsville School of Pharmacy, today ... pharmacists. The recommendations were release at the 29th Annual Scientific Meeting of the American ... ...
... ... specialist, citing a recent address by the U.S. Drug Control Policy Director, says government and ... interests will attempt to impede both. , ... Los Angeles (Vocus) May 6, 2010 -- Speaking to a coalition of anti-drug ...
... ... & Celebrity Centre Nashville mobilized Volunteer Ministers to staff shelters at Lipscomb University and ... flooded downtown Nashville, causing thousands of residents and visitors to evacuate homes and hotels. ... Nashville (Vocus) ...
Cached Medicine News:Health News:Chiropractic Stroke Website Launched To Aid Victims of Chiropractor Malpractice 2Health News:Accumed Research Associates Expands Capabilities In Phase I and Bioequivalence Clinical Trials 2Health News:Is Costa Rica Still the Best Place in Central America for Purchasing Real Estate? 2Health News:Is Costa Rica Still the Best Place in Central America for Purchasing Real Estate? 3Health News:SIUE Pain Summit Recommendations Announced Today 2Health News:SIUE Pain Summit Recommendations Announced Today 3Health News:Scientology Official Calls for Government-Community Cooperation to Attack Drug Abuse 2Health News:Church of Scientology Nashville Mobilizes Scientology Volunteer Ministers to Cope with Floods 2
... feature powerful, maintenance-free motors, and ... rotors for unparalleled application versatility. ... one: a high capacity general ... a high-speed centrifuge for separating ...
... Rotor has a standard 1.5ml rotor and 6 ... Easy operation (no switches to mess with). Simply ... the plastic tab to open. Starts and stops ... 2000 x g. Only five inches in diameter. ...
... Personal Micro Centrifuges MiniSpin and MiniSpin plus ... they are powerful enough so that each ... centrifuge for a wide range of molecular ... are available to meet your performance requirements. ...
Spectrafuge 16M High speed microcentrifuge. High g-force for molecular biology applications. Brushless, maintenance-free motor. Easy to use control panel. Complete with 18 x 1.5/2.0 ml rotor. StripSp...
Medicine Products: